Triple-negative breast cancer is one of the most aggressive forms of breast cancer, accounting for 10-15% of all breast cancer cases. Lacking estrogen, progesterone, and HER2 receptors, triple-negative breast cancer is unresponsive to common hormonal and HER2-targeted therapies, leaving patients with limited treatment options. Triple-negative breast cancer tumors are highly invasive and carry a high risk of recurrence, resulting in a poor prognosis and posing substantial challenges to conventional therapies.
A critical obstacle in treating triple-negative breast cancer effectively is its propensity for resistance to chemotherapy and progression through metastasis, driven by cancer stem cells within the tumor. These cells possess the ability to self-renew and regenerate the tumor after treatment, making them a key factor in the breast cancer cell’s resilience and recurrence.
At Acomhal Research, we have developed an innovative drug designed to target and eliminate breast cancer cells, including chemo-resistant cancer stem cells, while minimizing harm to surrounding healthy tissue.
Our Targeted Approach with Cx43-Based Therapy
Our novel drug is a mimetic peptide derived from a specific segment of Cx43, a protein essential for cell-to-cell communication. By disrupting Cx43 interactions within cancer cells, this therapy prevents the signaling pathways that fuel tumor growth and spread, providing a promising new approach to combatting triple-negative breast cancer’s aggressive nature and high recurrence rates.
